Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 13/20 | 0.67 |
| ▸ | P2RY6 | Q15077 | 9/20 | 0.61 |
| ▸ | P2RY4 | P51582 | 7/20 | 0.61 |
| ▸ | POLG | P54098 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1526683 | 1.00 | P2RY2 (0.67) | P2RY2P2RY6P2RY4POLG | |
| SCHEMBL20897112 | 0.93 | P2RY2 (0.67) | P2RY2P2RY6P2RY4POLG | |
| SCHEMBL4576249 | 0.92 | P2RY2 (0.67) | P2RY2P2RY6P2RY4POLG | |
| SCHEMBL1622183 | 0.92 | P2RY2 (0.67) | P2RY2P2RY6P2RY4POLG | |
| SCHEMBL1622177 | 0.92 | P2RY2 (0.67) | P2RY2P2RY6P2RY4POLG | |
| SCHEMBL4576341 | 0.91 | P2RY2 (0.66) | P2RY2P2RY6P2RY4POLG | |
| Cystetine Triphosphate SCHEMBL28678640 | 0.91 | P2RY2 (0.78) | P2RY2P2RY6P2RY4 | |
| Cystetine Triphosphate SCHEMBL26632567 | 0.91 | P2RY2 (0.78) | P2RY2P2RY6P2RY4 | |
| Cystetine Triphosphate SCHEMBL27657021 | 0.91 | P2RY2 (0.78) | P2RY2P2RY6P2RY4 | |
| SCHEMBL20769283 | 0.91 | P2RY2 (0.57) | P2RY2P2RY6P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 337 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240415958-A1 | MESSENGER RNA THERAPY FOR TREATMENT OF ARTICULAR DISEASE | TRANSLATE BIO INC (US) | 2024-12-19 | — | — | US | claimed |
| US-11998601-B2 | Messenger RNA therapy for treatment of articular disease | TRANSLATE BIO, INC. (US) | 2024-06-04 | — | — | US | claimed |
| EP-4739714-A1 | SINGLE DOMAIN ANTIBODIES FOR GPRC5D | Overland Therapeutics (US) Inc. (CN) | 2026-05-13 | — | — | EP | disclosed |
| EP-4736958-A2 | ANTI-5T4 ANTIBODIES AND USES THEREOF | Lepu Biopharma Co., Ltd. (CN) | 2026-05-06 | — | — | EP | disclosed |
| US-20260115317-A1 | GENE THERAPY | IMPERIAL COLLEGE INNOVATIONS LTD (GB) | 2026-04-30 | — | — | US | disclosed |
| US-12599560-B2 | Lipids and lipid nanoparticle formulations | LONGUIDE BIOPHARMA CORPORATION (CN) | 2026-04-14 | — | — | US | disclosed |
| US-12594245-B2 | Dry powder formulations for messenger RNA | TRANSLATE BIO, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| US-12569572-B2 | Messenger RNA therapy for the treatment of Friedreich's ataxia | TRANSLATE BIO, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-12564645-B2 | Methods for treatment of methylmalonic acidemia | TRANSLATE BIO, INC. (US) | 2026-03-03 | — | — | US | disclosed |
| US-12552858-B2 | Methods and compositions for delivering mRNA coded antibodies | TRANSLATE BIO, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-20260028422-A1 | Anti-MerTK ANTIBODIES AND USES THEREOF | CONCEPT TO MEDICINE BIOTECH CO LTD (CN) | 2026-01-29 | — | — | US | disclosed |
| US-20150140070-A1 | LIPID FORMULATIONS FOR DELIVERY OF MESSENGER RNA | TRANSLATE BIO, INC. | 2015-05-21 | — | — | US | disclosed |
| US-20150110859-A1 | MRNA THERAPY FOR ARGININOSUCCINATE SYNTHETASE DEFICIENCY | TRANSLATE BIO, INC. | 2015-04-23 | — | — | US | disclosed |
| US-20150110857-A1 | CNS DELIVERY OF MRNA AND USES THEREOF | TRANSLATE BIO, INC. | 2015-04-23 | — | — | US | disclosed |
| US-20150110858-A1 | MRNA THERAPY FOR PHENYLKETONURIA | TRANSLATE BIO, INC. | 2015-04-23 | — | — | US | disclosed |
| US-20130195867-A1 | RNA-CODED ANTIBODY | CUREVAC GMBH (DE) | 2013-08-01 | — | — | US | disclosed |
| US-20100189729-A1 | RNA-CODED ANTIBODY | CURVAC GMBH (DE) | 2010-07-29 | — | — | US | disclosed |
| US-20090118223-A1 | Novel 2'-c-methyl and 4'c-methyl nucleoside derivatives | MERCK SHARP & DOHME CORP. | 2009-05-07 | — | — | US | disclosed |
| EP-1915053-A2 | NOVEL 2'-C-METHYL AND 4'-C-METHYL NUCLEOSIDE DERIVATIVES | Merck & Co., Inc. (US) | 2008-04-30 | — | — | EP | disclosed |
| WO-2007022073-A2 | NOVEL 2'-C-METHYL AND 4'-C-METHYL NUCLEOSIDE DERIVATIVES | MERCK & CO., INC. (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12599560-B2 | Lipids and lipid nanoparticle formulations | NPC1, NPC1L1, NSUN3 | P2RY2 4697/4885P2RY6 4585/4885P2RY4 4717/4885 |
| US-12569572-B2 | Messenger RNA therapy for the treatment of Friedreich's ataxia | SMN1; SMN2, CDR2, ATXN2 | P2RY2 1673/4885P2RY6 2994/4885P2RY4 2577/4885 |
| US-20150110858-A1 | MRNA THERAPY FOR PHENYLKETONURIA | PAH, NSUN3, METTL16 | P2RY2 4772/4885P2RY6 4157/4885P2RY4 4774/4885 |
| US-12552858-B2 | Methods and compositions for delivering mRNA coded antibodies | CD2BP2, IL2RA, CD22 | P2RY2 3641/4885P2RY6 4051/4885P2RY4 3695/4885 |
| US-20150110857-A1 | CNS DELIVERY OF MRNA AND USES THEREOF | SMN1; SMN2, PMP22, CLN6 | P2RY2 3949/4885P2RY6 3745/4885P2RY4 4317/4885 |
| US-12564645-B2 | Methods for treatment of methylmalonic acidemia | MMAB, METTL16, COASY | P2RY2 4719/4885P2RY6 4652/4885P2RY4 4731/4885 |
| US-20240415958-A1 | MESSENGER RNA THERAPY FOR TREATMENT OF ARTICULAR DISEASE | NSUN3, RNMT, TRDMT1 | P2RY2 3741/4885P2RY6 3298/4885P2RY4 4107/4885 |
| US-20150140070-A1 | LIPID FORMULATIONS FOR DELIVERY OF MESSENGER RNA | RNMT, NSUN3, IGF2BP3 | P2RY2 4576/4885P2RY6 4557/4885P2RY4 4827/4885 |
| US-20260028422-A1 | Anti-MerTK ANTIBODIES AND USES THEREOF | IGLV6-57, MERTK, IGSF11 | P2RY2 3915/4885P2RY6 4377/4885P2RY4 4308/4885 |
| US-11998601-B2 | Messenger RNA therapy for treatment of articular disease | NSUN3, RNMT, TRDMT1 | P2RY2 3741/4885P2RY6 3298/4885P2RY4 4107/4885 |
| US-20090118223-A1 | Novel 2'-c-methyl and 4'c-methyl nucleoside derivatives | MTAP, NT5C3B, NSUN2 | P2RY2 679/4885P2RY6 592/4885P2RY4 413/4885 |
| US-20260115317-A1 | GENE THERAPY | CCL11, MPO, GSTA2 | P2RY2 3535/4885P2RY6 2469/4885P2RY4 3504/4885 |
| US-12594245-B2 | Dry powder formulations for messenger RNA | METTL16, RBM25, RNMT | P2RY2 942/4885P2RY6 2292/4885P2RY4 3568/4885 |
| US-20150110859-A1 | MRNA THERAPY FOR ARGININOSUCCINATE SYNTHETASE DEFICIENCY | ASS1, ADSS2, AARS1 | P2RY2 4639/4885P2RY6 4431/4885P2RY4 4806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.